利润表显示利息费用从2021年开始下降,2022年变为了利息收入,消除了利息负担。
2023Q1营收大幅下滑59%,营业利润和净利润均转亏,盈利...查看全文
Scottishgirl2022-08-06 04:12
$德纳维制药(DVAX)$ all in this one for long at between $9-10, going to hold it long!查看全文
nomage2022-05-26 14:09
很多朋友无法想明白一个问题,为什么是三叶草生物的疫苗,为什么CEPI和GAVI就这么渴望它?
原因非常简单,除了我一直说的三叶草疫苗的四个特点以外——1成本在所有疫苗路径中最低(重组蛋白是最低的,而三叶草成本比novavax还低)2储存运输要求低成本低 3 产能爆发迅速 4 全球大型三期临床效果...查看全文
nomage2022-05-26 11:59
$三叶草生物-B(02197)$ 的佐剂公司$德纳维制药(DVAX)$ ,已经开始全面启动(而且是在美股非常萧条的前提下,完全的逆势而动),其合作的法国灭活疫苗企业一年的产量仅仅几千万支,那么能支撑德纳维真正业绩增长的是谁?大家好好想想。查看全文
nomage2022-05-20 10:55
回复@bluesky371: 并不过剩尤其是三叶草的市场,我说了CEPI和WHO就是要求三叶草一定要提供数十亿剂的疫苗满足中低收入国家的疫苗需求。这些国家目前的施打率10%。另外nature杂志昨天说了,得omicron并不会产生对原始株和delta 等烈性株的抗原,但打过高质量原始株疫苗的人得过omicron将获得强大的...查看全文
nomage2022-05-18 12:39
已经观察了一阵三叶草,但先申明:以下不作为投资建议,仅仅作为个人收集信息的分享。
1 三叶草生物裁员
事实上,不仅没有裁员,三叶草目前仍然在不断的招聘新员工(生产和研发都在大力招聘),上海的研发总部年中会新招100多人。而且据内部员工反映从去年至今工作强度已经达到了997,可谓...查看全文
美东时间 2011-09-07 02:40 Dynavax Technologies Corp at William Blair & Company, LLC Life Sciences Conference
8-K - Current report Filed: 2011-05-19 AccNo: 0001181431-11-031138 Size: 13 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 网页链接
8-K - Current report Filed: 2011-05-19 AccNo: 0001181431-11-031138 Size: 13 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 网页链接
10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2011-05-06 AccNo: 0001193125-11-130978 Size: 565 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-068141 Size: 4 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065584 Size: 7 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065581 Size: 7 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065592 Size: 7 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065588 Size: 7 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065571 Size: 12 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065573 Size: 7 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065578 Size: 7 KB 网页链接
$德纳维制药(DVAX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-065576 Size: 7 KB 网页链接
$德纳维制药(DVAX)$ 8-K Current report, items 5.02 and 5.07 Accession Number: 0000950170-24-064556 Act: 34 Size: 177 KB 网页链接